Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Everolimus stories

Nov 17, 2026

FDA approves Roche's giredestrant pill for advanced breast cancer

The FDA approved Roche's oral SERD giredestrant in combination with Novartis's everolimus for advanced or metastatic breast cancer, reducing risk of progression or death by 62%. This marks Roche's entry into the competitive SERD market.

Nov 17, 2026·3 sources
00

Top claims

  • ▪The FDA approved giredestrant in combination with everolimus for patients with locally advanced or metastatic ER-positive, HER2-negative, ESR1-mutated breast cancer whose disease recurred or progressed on endocrine therapy
  • ▪An FDA approval of giredestrant for earlier stages of breast cancer would make the medication available to a larger group of patients
  • ▪Prescribing information for giredestrant contains official warnings and precautions regarding the risks of bradycardia and embryo-fetal toxicity

Topics

Clinical trialsPrecision medicineFDA drug approvalDrug Policy, Pricing & ApprovalCancer treatmentTargeted cancer therapyCancer and Cancer TreatmentOncologyCancer & Oncology